Oct 14 (Reuters) - Denmark's H Lundbeck A/S

has agreed to buy Longboard Pharmaceuticals ( LBPH ) in a $2.6

billion deal to boost its pipeline of treatments for neuro-rare

conditions, sending shares of the U.S.-based company up 43.9% in

premarket trading.

The companies said Lundbeck will acquire all of Longboard's

shares for $60 per share, which represents a premium of 54.2% to

the stock's last close of $38.90.

Longboard's lead drug candidate, bexicaserin, for seizures

associated with a group of epilepsies is in late-stage

development.

(Reporting by Manas Mishra and Puyaan Singh in Bengaluru;

Editing by Shinjini Ganguli)